Apoptosis is the death of cells that occurs as a normal and controlled part of an organism’s growth or development. The proper valency is required to trigger DR5-mediated apoptosis of cancer cells while sparing healthy cells.
The Candidate
Our tetravalent DR5 agonist.
ozekibart (INBRX-109), our tetravalent DR5 agonist, is designed to:
- Promote tumor-biased cell death by activating DR5.
- Potently induce DR5 receptor clustering and subsequent activation of cell death.
- Achieve optimal DR5 agonism and safety.
- Eliminate recognition by pre-existing antidrug antibodies to lessen the potential for toxic hyperclustering.
Valency Drives DR5-Mediated Apoptosis
ozekibart (INBRX-109) Clinical Trials
The registration-enabling phase 2 trial for ozekibart (INBRX-109) (NCT04950075) is in patients with unresectable or metastatic conventional chondrosarcoma.
The phase 1 trial for ozekibart (INBRX-109) (NCT03715933) currently enrolls patients with Ewing sarcoma.